Lung cancer is the most frequently diagnosed cancer and the leading cause of cancer mortality worldwide. Patients may suffer from one of two cancer types: Non-Small Cell Lung Cancer (NSCLC), or the less common, Small-Cell Lung Cancer (SCLC).

Cancer biomarkers are effective for prognostic evaluation and monitoring of disease. MonoTotal® is a sensitive and efficient tool for the management of patients with Non-Small Cell Lung Cancer (NSCLC).

With MonoTotal®, physicians receive an early indication of disease status, measured in terms of tumor cell activity rather than more conventional tumor burden measurements. MonoTotal® provides the physician with a reliable monitoring aid for disease progression and treatment in lung cancer patients.

About Lung Cancer
Lung cancer kills more people than colon, breast, and prostate cancer combined (WHO statistics). An estimated 80-85 percent of lung cancer patients suffer from Non-Small Cell Lung Cancer (NSCLC). With approximately 15-20 percent of lung cancer patients diagnosed when the disease is still restricted to the lungs, early detection is critical to increasing the patient’s chances of survival. Surgical resection is one effective treatment for early stage NSCLC; however, the majority of patients suffer from an advanced and inoperable stage of the disease.